1 **Insights into the relationship between nasal bacterial composition and**
2 **susceptibility to early-life respiratory disease: a pilot observational study.**
3

4 Jose A. Caparrós-Martín[1,2,3], Elizabeth Kicic-Starcevich[3], Patricia Agudelo-
5 Romero[3,4,5], David G Hancock[1,3,6], Thomas Iosifidis[1,3,7,8], Yuliya V
6 Karpievitch[3,7,9], David J Martino[3], Guicheng Zhang[1,7], Desiree T Silva[1,7,10,11,12],
7 Anthony Bosco[13,14], Susan L Prescott[1,10,15], Peter N LeSouëf[1,3], Anthony
8 Kicic[3,7,8], Stephen M. Stick[6,8].
9

[1]UWA Medical School, UWA Centre for Child Health Research, The University
of Western Australia, Perth, Western Australia, Australia.
[2]Curtin Health and Innovation Research Institute (CHIRI), Curtin University,
Perth, Western Australia, Australia.
[3]Wal-yan Respiratory Research Centre, The Kids Research Institute Australia,
The University of Western Australia, Perth, Western Australia, Australia.
[4]Australian Research Council Centre of Excellence in Plant Energy Biology,
School of Molecular Sciences, The University of Western Australia, Perth,
Western Australia, Australia.
[5]European Virus Bioinformatics Centre, Friedrich-Schiller-Universität Jena,
07737, Thuringia, Germany.
[6]Department of Sleep and Respiratory Medicine, Perth Children's Hospital,
Perth, Western Australia, Australia.
[7]School of Population Health, Curtin University, Bentley, Western Australia,
Australia.
[8]Centre for Cell Therapy and Regenerative Medicine, School of Medicine and
Pharmacology, The University of Western Australia and Harry Perkins Institute
of Medical Research, Perth, Western Australia, Australia.
[9]School of Biomedical Sciences, The University of Western Australia, Perth,
Western Australia, Australia.
[10]The Kids Research Institute Australia, The University of Western Australia,
Nedlands, WA, Australia.
[11]School of Medical and Health Sciences, Edith Cowan University, Perth,
Western Australia, Australia.

[12]Department of Paediatrics and Neonatology, Joondalup Health Campus,
Perth, Western Australia, Australia.

[13]Asthma and Airway Disease Research Center University of Arizona Tucson,
Arizona.

[14]Department of Immunobiology, The University of Arizona College of Medicine
Tucson, Arizona.

[15]Nova Institute for Health, Baltimore, Maryland, United States; Department of
Family and Community Medicine, University of Maryland, Baltimore, Maryland,
United States.

Correspondence to:

Dr Jose A Caparros-Martin; The University of Western Australia, Perth, Western

Australia, Australia; Email: joseantonio.caparrosmartin@uwa.edu.au

Dr Thomas Iosifidis; Wal-yan Respiratory Research Centre, The Kids Research

Institute Australia, The University of Western Australia, Perth, Western

Australia, Australia; Email: thomas.iosifidis@thekids.org.au

Professor Stephen M. Stick; Department of Sleep and Respiratory Medicine,

Perth Children's Hospital, Perth, Western Australia, Australia;   Email:

Stephen.stick@health.wa.gov.au

Abstract

Background. Early-life susceptibility to viral respiratory infections is associated with long-term respiratory morbidity in children. Currently, no reliable tools exist to predict susceptibility to these infections. Given its role in modulating pathogen virulence and airway inflammation, the endogenous microbiota represents a potential target for prevention. In this pilot study, we investigated whether distinct nasal microbial communities are associated with viral respiratory disease and respiratory phenotypes during the first year of life.

Methods. We analyzed 90 nasal swabs from 55 infants enrolled in the AERIAL study, representing background samples collected at schedule visits (~4 months old) and samples from symptomatic episodes. Bacterial profiling was done blinded to clinical data via full-length *16S rRNA* sequencing, and bacterial load was quantified using a pan-bacterial TaqMan® assay.

Results. Nasal bacterial diversity was similar between background and symptomatic swabs, with community composition differences largely driven by inter-individual variation. In paired samples, symptomatic swabs showed reduced diversity but no change in bacterial load. Virus-bacteria interactions were observed in rhinovirus-positive swabs, but not in SARS-CoV-2-positive swabs. Two distinct bacterial endotypes were identified, enriched in either *Moraxella* or *Streptococcus* species and differing in alpha diversity. In background swabs, microbial endotypes were not associated with the number of symptomatic swabs or bronchiolitis episodes. We observed a potential sex-specific association between background swabs endotypes and number of wheezing episodes, which warrants further investigation in follow-up studies.

Conclusion. Our pilot data suggest that the nasal microbiota might influence wheezing outcomes in a sex-specific manner, highlighting the need for larger, longitudinal investigations.

Keywords Viral infection, respiratory epithelia, nasal microbiota, ORIGINS.

Introduction

Acute respiratory infections are a leading cause of death in children under five and a significant source of morbidity, particularly among newborns and infants (1). Most symptomatic viral respiratory infections occur early in life, with recurrent infections associated with an increased risk of developing chronic wheezing disorders during childhood (2, 3). Wheezing disorders including recurrent wheeze and asthma, are among the most prevalent pediatric respiratory illnesses (4). Rates and severity are highest in vulnerable populations, such as Indigenous children, lower-socioeconomic backgrounds, or children with underlying chronic diseases (4). Despite this burden, no clinically validated biomarkers exist to reliably predict which children will develop severe or persistent respiratory disease (4).

Longitudinal studies have shown that nasopharyngeal colonization trajectories influence the risk of respiratory infections during infancy and the later development of asthma and related wheezing disorders (5,6). In early life, the nasopharyngeal microbiota transitions from a community dominated by maternal *Staphylococcus* species to one enriched with *Corynebacterium*, *Dolosigranulum*, or *Moraxella*, with transient colonization by *Haemophilus* or *Streptococcus* (6,7). Early acquisition of stable, pathogen-dominated communities has been linked to airway inflammation and increased respiratory morbidity (5,6,8-12). For example, a recent study found that profiles dominated by *Haemophilus* and *Moraxella* are associated with early interferon-related epithelial responses and pro-inflammatory airway environments (5), whereas *Corynebacterium*-enriched communities correlated with respiratory health (5,6). However, findings across studies vary, with some reporting that *Moraxella*-dominated communities are associated with fewer upper respiratory tract infections and greater protection against viral infections in both adults and children (13-15). These discrepancies may stem, in part, from the limitations of targeting fragments of the *16S rRNA* gene, which do not provide sufficient resolution to determine species-level taxonomy (16).

While the nasopharyngeal microbiota have been well studied, it remains unclear whether nasal microbial communities, which are at the frontline of viral exposure, are associated with viral infection outcomes. In this pilot study, we used full-length *16S rRNA* sequencing to profile the bacteria associated with

130 nasal swabs from the Airway Epithelium Respiratory Illnesses and Allergy
131 (AERIAL) birth cohort (17) and explore whether specific bacterial communities
132 are associated with susceptibility to symptomatic respiratory infections and
133 respiratory phenotypes in the first year of life.
134

Material and methods

AERIAL study cohort

We profiled the microbiota associated with the nasal epithelium in nasal swabs
collected from healthy infants participating in the Airway Epithelium Respiratory
Illnesses and Allergy (AERIAL) birth cohort study (17). Ethical approval for
AERIAL was obtained from Ramsey Health Care HREC WA-SA (reference
number 1908). AERIAL is a sub study nested within the ORIGINS cohort
(18,19), with the central objective of evaluating whether a dysfunctional
epithelium exists at birth, and whether this increases the risk for developing
respiratory pathologies later in life (17). A unique aspect of the AERIAL study is
the use of a smart phone app for real-time monitoring of respiratory symptoms
(17, 20). AERIAL also collected longitudinal nasal swabs (FLoQSwab®, Copan
Group, Italy) during predefined asymptomatic collection timepoints at
approximately 3, 6, and 9 months of age, as well as during symptomatic
episodes triggered by app alerts (17). Symptomatic swabs were defined by
either a temperature >37.5°C along with at least one symptom (runny/blocked
nose, cough, sneeze, headache, myalgia, chills, rigors, tiredness, sore throat,
dyspnea, loss of taste/smell, poor feeding, or diarrhea), or a temperature
<37.5°C with at least two respiratory symptoms present (17).

Clinical data for AERIAL study participants collected as part of ORIGINS (18)
included maternal and infant demographics, and medical history for both
mothers and infants amongst others (17,18). Additional clinical information on
respiratory disease collected as part of the AERIAL study protocol, covered
respiratory illness events, wheezing, allergies, and relevant respiratory
medications used during scheduled visits and symptomatic episodes (17).
160

Study size

This pilot study was designed as an exploratory investigation to examine
potential associations and estimate effect sizes to inform future, larger-scale

studies. A formal power calculation was not performed, consistent with the pilot
nature of the work. Instead, we analysed a subset of participants randomly
selected from the cohort at the time, to ensure feasibility within available
resources while maintaining representativeness of the broader population.
168

Sample collection
Both nostrils were sampled at scheduled visits and when a symptomatic
episode was recorded through the smartphone app. One swab (FLoQSwab®,
Copan Group, Italy) was placed in viral transport media (eSwab, Copan Group,
Italy) and assayed against a qPCR panel for 8 common respiratory viruses at
commercial laboratory Western Diagnostics Pathology Pty Ltd, Western
Australia (17). The qPCR panel was designed to detect Influenza "A" and "B",
respiratory syncytial virus, human metapneumovirus, parainfluenza, rhinovirus,
adenovirus and SARS-CoV-2. The second swab was placed in 1 mL of eNAT®
buffer (eNAT®, Copan Group, Italy), transported to the laboratory at 4°C and
subsequently stored at -80°C until processing for microbiome analyses (17).
180

Isolation of microbial DNA from nasal swabs, amplification of the full-
length 16S rRNA gene and sequencing of the amplicon pools
Blinded to clinical data, we extracted bacterial DNA from 400 µL of eNAT®
extract using the QIAamp DNA kit (QIAGEN). The recommended protocol was
modified to include a bead-beating pre-processing step using 0.1 mm diameter
zirconia/silica beads (BioSpec) as we previously described (21). Prior to the
binding step, we added 100 µg of yeast tRNA carrier (ThermoFisher) to
enhance DNA recovery. To identify reagent-related contaminants, negative
extraction controls were processed alongside the swab specimens. We used a
full-length *16S rRNA* gene amplicon sequencing approach to profile the
bacterial component of the nasal epithelium-associated microbiota. Amplicon
library preparation and sequencing were done at the Australian Genome
Research Facility (AGRF Ltd, Melbourne, VIC, Australia). Briefly, for
amplification of the full-length *16S rRNA* bacterial gene we used the
degenerated forward 5'-*GCATC/barcode/AGRGTTYGATYMTGGCTCAG* and
reverse 5'-*GCATC/barcode/RGYTACCTTGTTACGACTT* primers following the
protocol recommended by PacBio (https://www.pacb.com/wp-

content/uploads/Procedure-checklist-Amplification-of-bacterial-full-length-16S-
rRNA-gene-with-barcoded-primers.pdf). Individual PCR reactions showing the
amplification of a single PCR product of the expected size are represented in
Figure S1. Libraries were prepared using the SMRTbell® preparation kit 3.0,
and sequenced using the Sequel II binding kit 3.1, on a single SMRT cell 8M,
using a PacBio Sequel IIe instrument.
To minimize bias associated with amplifying and sequencing the *16SrRNA* gene
in DNA extracts obtained from low bacterial biomass samples we followed two
strategies: parallel DNA extraction and sequencing from eNAT® buffer negative
controls, and bacterial load quantification of the DNA extracts using a pan
bacteria TaqMan® assay (22). Details on the TaqMan® assay are described in
our previous publication (23).
210
Processing of the sequencing data
Data was processed using *DADA2* (v1.28.0) (24), as implemented in the nfcore
pipeline ampliseq (v2.8.0) (https://nfco.re/ampliseq), using Nextflow (v25.04.2)
(25). For taxonomic classification of the generated amplicon sequencing
variants (ASVs), we used the naïve Bayesian classifier implemented in *DADA2*
(26), and a pretrained Genome Taxonomy Database (GTDB; vR09-RS220) as
reference library (27). To prevent bias from potential contaminants and
distinguish a true biological signal from background noise, we followed the
analytical workflow outlined in our previous work (28). Briefly, only bacterial
DNA extracts with qPCR result values higher than 3 standard deviations from
the mean result in negative extraction controls were retained for further
analyses (Figure S2). Then, the taxonomic profiles in the negative extraction
controls were used to identify and remove potential contaminants using the R
package *decontam* (v1.20.0) (29) (Table S1-S2). We performed Procrustes
analysis to confirm that the described filtering steps did not significantly impact
the overall structure of the original, unfiltered taxonomic data table (Table S3
and Figure S3). After filtering, we removed a sample with only 136 reads from
further analyses.
229
Statistical analysis

Analyses were done in R statistical software (v4.3.0) within the RStudio
environment (v2023.03.0). The R code and the deidentified datasets required to
reproduce the findings of this study are available in the accompanying GitHub
repository: https://github.com/jacapmar/MicrobiomeAERIAL. We used vegan
(v2.6-4) for conducting permutational multivariate analysis of variance
(PERMANOVA) and Procrustes analyses, and to calculate ecological diversity
indexes. PERMANOVA was performed on a beta diversity distance matrix
constructed using Aitchison distances. Principal Component Analysis (PCA)
was done using the functions contained in the MixOmics package (v6.24.0)
(30). To address the compositional nature of the microbiome data, a centered
log-ratio (CLR) transformation was applied to the full taxonomy table before
performing correlation-based analyses, including PCA and Spearman's rank
correlation. For probabilistic modelling of microbial compositional profiles, we
used Dirichlet Multinomial Mixtures (DMM) models as implemented in the R
package DirichletMultinomial (v1.42.0) (31). Differential abundance analysis
was performed using the Analysis of Compositions of Microbiomes with Bias
Correction framework, as implemented in the *ancombc2* function from the
ANCOMBC R package (v2.2.0) (32). According to the normality of the data and
the hypotheses being tested, we also used Student's t-test and Wilcoxon Rank
Sum Test. When multiple hypotheses were tested simultaneously, the false
discovery rate method was used to control the type I error rate. Categorical data
in contingency tables were compared using the Fisher exact test. Linear models
were employed using the R built-in function *lm*. Logistic regression was fitted
using the *glm* function in R. Count data was initially modelled using Poisson
regression as implemented in the R built-in function *glm*. To evaluate the validity
of the Poisson distributional assumption (that the mean equals the variance),
we applied the *dispersiontest* function from the AER package in R (v1.2-14).
This score test evaluates overdispersion based on Pearson residuals and the
residual deviance. When overdispersion was detected (i.e., variance
significantly greater than the mean), models were refitted using a negative
binomial regression, which accounts for extra-Poisson variation by including a
dispersion parameter. Negative binomial regression was fitted using the *glm.nb*
function of the R package MASS (v7.3-60). Incidence risk ratios with 95%
confidence intervals were calculated from the coefficients of the GLM and

GLM.nb models. Marginal effects were estimated using the *ggpredict* function
from the ggeffects package (v2.2.1) in R. We used the R packages tidyverse
(v2.0.0) for data manipulation and ggplot2 (v3.4.2) for data visualization.
Figures were created using Adobe Illustrator (v24.1). The cut-off for statistical
significance was set at $p<0.05$.
270

Results
Study cohort
A subset of 90 swabs from the AERIAL biobank was included in this study.
Clinical metadata for the individuals represented in this swab cohort is provided
in Table S4 and summarized in Table 1. These 90 swabs were collected from
55 randomly selected infants, of whom 30 (54%) were female. Forty-one swabs
were obtained during scheduled visits (hereafter also referred to as background
swabs), representing the nasal microbiota in the absence of respiratory
symptoms. Background swabs were collected at 3-month (n=24, 58.5%), 6-
month (n=15, 36.6%), or 9-month (n=2, 4.9%) visits (median age [IQR]: 131
days [104–200]). The median age for symptomatic swabs was 188 days (IQR
[145-245]). Paired swabs consisting of a background swab and the first
symptomatic episode collected after that background swab, were available for
33 infants. For one infant, two background and two symptomatic swabs were
present in this cohort, but only one background and one symptomatic swab
produced microbiome data.
In our cohort, 50 swabs tested positive for respiratory viruses by qPCR,
including two background swabs and 48 symptomatic swabs (Table 1). Of the
positive background swabs, one was positive for rhinovirus and one for SARS-
CoV-2 (Table 1 and Table S4). Among symptomatic swabs, the most frequently
detected viruses were rhinovirus (28, 56%) and SARS-CoV-2 (23, 46%) (Table
1 and Table S4). Five symptomatic swabs from five participants showed
polyviral infections: SARS-CoV-2 and rhinovirus were detected together in three
swabs; SARS-CoV-2, rhinovirus, and adenovirus in one swab; and rhinovirus,
adenovirus, and parainfluenza in another (Table S4).
296

Characterization of the swab-associated nasal bacterial communities.

We obtained reliable microbial profiles from 71 (~79%) swab samples, of which
36 (~51%) represented background swabs. In line with previous findings from
Western Australian cohorts (6,12), the swab-associated bacterial profiles
included commensal taxa and opportunistic pathogens commonly found in the
nasopharynx of healthy infants and children, including species from the genera
Moraxella and *Streptococcus* (Figure S4). The most abundant features in our
cohort were amplicon sequence variants (ASVs) assigned to the following taxa:
Moraxella nonliquefaciens (mean [standard deviation (SD)]: 22.55% [36.42],
prevalence 36.62%), *Moraxella catarrhalis* (13.71% [28.16], prevalence
43.66%), and *Streptococcus* (12.14% [16.94], prevalence 85.91%).
The nasal microbiota of some infants was characterized by the presence of
respiratory pathogens (Figure S4). Given the established associations between
early colonization by *Moraxella catarrhalis* or *Streptococcus pneumoniae* and
increased susceptibility to respiratory infections and adverse respiratory
phenotypes (5,9,11,12), we compared in our cohort the abundance of these
pathogens between background and symptomatic swabs. Symptomatic swabs
were characterized by higher relative abundance of *Streptococcus pneumoniae*
(mean [SD]; background, 0.1% [0.5]; symptomatic, 4.3% [14.9]; Wilcoxon rank
sum test (WRST) with false discovery rate (FDR) correction (*r*=0.27, *p*=0.044))
(Figure S5). However, we did not observe differences in the abundance of
Moraxella catarrhalis (mean [SD]; background, 11.8% [28]; symptomatic, 15.6%
[28.6]; WRST with FDR correction (*r*=0.12, *p*=0.32)) (Figure S5).
320

Interaction between respiratory viruses and bacterial taxa in the nose.
Previous research has demonstrated alterations in the composition of the nasal
microbiota associated with respiratory viruses and suggested that these viruses
can influence bacterial pathogen virulence (6,9,33). To explore potential
multilevel interactions in our dataset, we focused our correlation analyses on
the top three ASVs, which together accounted for 60% of the cumulative
abundance (Figure 1A), and the two most frequently detected viruses;
rhinovirus and SARS-CoV-2 (Table 1). Detection of rhinovirus was positively
correlated with *Moraxella catarrhalis* (*ρ* = 0.37, FDR-adjusted *p* = 0.004), and
negatively correlated with *Streptococcus* (*ρ* = -0.47, FDR-adjusted *p* = 0.0002),
while SARS-CoV-2 showed no significant correlations with any of the bacterial

features analyzed (Figure 1B). Notably, bacterial alpha diversity in rhinovirus-positive symptomatic swabs was lower than in symptomatic swabs positive for SARS-CoV-2 (WRST, p = 0.021; Figure 1C). Likewise, differential abundance analysis at the species level using ANCOM-BC2 revealed that *Moraxella catarrhalis* was the only feature significantly enriched in rhinovirus-infected samples, with a fold change of 7.44 (95% CI: 2.39–23.18; adjusted p = 0.01). Conversely, bacterial load in symptomatic swabs did not vary with the virus detected (Figure 1D).

Microbial community analysis across symptomatic and background swabs.

Next, we evaluated community structural variation between samples collected during scheduled visits and those taken during a symptomatic episode. The PERMANOVA results suggest that the type of swab (whether background or symptomatic) was not a primary contributor to bacterial community composition variation (PERMANOVA: pseudo-F=0.99, R²=0.01, p=0.38). This is further supported by the principal component analysis represented in Figure S6, which shows a high overlap between bacterial communities from background and symptomatic swabs. Similarly, we did not observe differences between swabs collected at scheduled visits or during symptomatic episodes in bacterial load (median [IQR]: background: 0.038 [0.036-0.041]; symptomatic: 0.038 [0.036-0.042]; WRST (r=0.01, p=0.92)) or alpha diversity (median [IQR]: background: 1.39 [0.7-1.79]; symptomatic: 1.03 [0.57-1.92]; WRST (r=0.07, p=0.60)) (Figure 2A-B). In contrast, PERMANOVA analysis demonstrated that most of the variance in our dataset (83%) was explained by interindividual differences (pseudo-F=2.53, R²=0.83, p=0.0001), while sex accounted for little variation (pseudo-F=1.12, R²=0.02, p=0.31), suggesting that other environmental covariates may play a more prominent role in shaping bacterial community composition in the nose.

To address the high inter-individual variation in our swab cohort, we focused our next analyses on longitudinal data, specifically comparing background and subsequent symptomatic swabs obtained from the same infant. We observed a reduction in bacterial alpha diversity in symptomatic swabs (paired WRST p=0.039)), while bacterial load remained unaffected (mean difference [95%

confidence interval (CI)]: -0.001 [-0.003-0.0009], paired t-test p=0.23) (Figure 2C-D).

Associations between bacterial community structure and future respiratory outcomes.

To evaluate the existence of bacterial community structures associated with risk of respiratory disease, we performed a probabilistic modelling of the bacterial community data using Dirichlet Multinomial Mixtures (31). We identified two microbial community types, hereafter referred to as endotype 1 and endotype 2. Endotype 1 was defined by four ASVs assigned to *Moraxella nonliquefaciens*, *Moraxella catarrhalis*, *Streptococcus*, and *Corynebacterium pseudodiphtheriticum* (Figure 3B and Figure S7). In contrast, endotype 2 was primarily defined by an ASV assigned to the *Streptococcus* genus (Figure 3B and Figure S7). Alpha diversity in endotype 2 was higher than in endotype 1 (median [IQR], endotype 1: 0.67 [0.34-0.96]; endotype 2: 1.86[1.52-2.40]; WRST (r=0.77, p=8.56x10^{-14})) (Figure 3C). Neither of the two endotypes was associated with sex (p=0.19, Fisher exact test FET) or seasonality (p=0.93, FET) (Figure S8). Similarly, the microbial community type present in background swabs was not associated with childcare attendance (p=0.58, FET). (Figure S8C).

In our dataset, children classified in endotype 1 had an expected rate of 2.53 wheezing episodes during the first year of life (95% CI: 1.34–5.23, p=0.007). Compared to endotype 1, those in endotype 2 exhibited a non-significant reduction in wheezing frequency (IRR=0.56, 95% CI: 0.22–1.40, p=0.22), suggesting a potential but statistically inconclusive association between nasal microbial endotypes and the number of wheezing episodes (Figure S9A). Similarly, Individuals in endotype 2 had a later onset of wheeze by an estimated 2.39 months compared to endotype 1, although this association was not significant (β=2.39, 95% CI: -0.55-5.34, F(1, 21)=2.85, p=0.106) (Figure 3D).

Building on prior research that identified sex-specific early-life risk factors for wheeze, we investigated whether nasal microbial endotypes showed a similar sex-specific pattern (34). Among females with endotype 1 (*Moraxella*-dominated), the rate of wheezing episodes in the first year of life was highest (IRR=4.00, 95% CI: 1.57–12.83, p=0.008; Figure 3E). In contrast, females with

endotype 2 (*Streptococcus*-dominated) had a significantly lower rate of
episodes (IRR=0.18, 95% CI: 0.04–0.69, *p*=0.016), indicating an approximate
82% reduction compared to endotype 1 (Figure 3E, Figure S9B). Although male
sex was not significantly associated with wheezing within endotype 1
(IRR=0.45, 95% CI: 0.12–1.65, *p*=0.23), we observed a significant interaction
between male sex and endotype 2 (IRR=6.72, 95% CI: 1.03–43.72, *p*=0.036),
suggesting that the effect of endotype 2 differs by sex. Specifically, while
endotype 2 was protective in female, this effect was absent in males.
Classification of samples into endotypes using a different probabilistic mixed
model (Latent Dirichlet Allocation) yielded results comparable to those obtained
with the DMM approach (Figure S10).
While the sex–endotype interaction was statistically significant, we identified a
single influential data point with high leverage: a female participant with
endotype 1 who experienced 14 wheezing episodes in the first year (Table S4,
infant_11). Although this data point is valid and reflects natural variation in our
cohort, its removal rendered the association non-significant, indicating
sensitivity to individual cases (Figure S11). Thus, our findings suggesting a sex-
specific link between the nasal microbiota endotypes and wheezing outcomes
should be interpreted with caution and warrant validation in larger, independent
datasets.
We found no association between background swab endotypes and the number
of symptomatic swabs or bronchiolitis episodes during the first year of life
(Figure S12A-B). Similar results were observed after adjusting for sex (Figure
S12C-D). Similarly, compared to endotype 1, endotype 2 was not associated
with the odds of wheezing (Odds Ratio [OR]=0.48, 95% CI: 0.11–1.96, *p*=0.32),
recurrent wheezing (OR=0.47, 95% CI: 0.11–1.98, *p*=0.30), or bronchiolitis
(OR=0.86, 95% CI: 0.18–4.16, *p*=0.84) during the first year of life, even after
adjusting the models by sex (Figure S13).
To account for interindividual responses, we examined temporal transitions in
nasal microbial endotypes between paired background and symptomatic swab
samples collected from the same individuals, and linked these transition
patterns to respiratory phenotypes, including the number of wheezing episodes
and symptomatic swabs during the first year of life (Figure S14). We observed
three types of transitions: from endotype 1 to endotype 1, from endotype 2 to

endotype 1, and from endotype 2 to endotype 2. Notably, no participants transitioned from endotype 1 to endotype 2, suggesting a high degree of stability for endotype 1 during symptomatic episodes. Despite these patterns, we observed no significant differences in the number of wheezing episodes or symptomatic swabs across the transition groups (Figure S14).

Discussion

In this observational study, we characterized the nasal microbiota of infants naturally exposed to respiratory viruses during their first year of life in a well-phenotyped infant cohort. We compared samples collected during scheduled visits with those taken during episodes of respiratory symptoms to identify microbial patterns linked to respiratory disease phenotypes.

We observed a complex and variable structure in the nasal microbiota, with several ASVs assigned to species from multiple genera, including *Streptococcus* and *Moraxella*. This contrasts with previous studies of the nasopharynx, which have reported that early-life microbial communities are typically simpler and dominated by a single taxon, either a commensal or a potential pathogen, such as *Corynebacterium* or *Moraxella* (5,6,11–13). While technical factors, such as the use of full-length *16S rRNA* gene sequencing (which provides improved taxonomic resolution), may in part explain these differences, it is also plausible that the anterior nares, being more exposed to the external environment, support greater microbial diversity and turnover than the more protected nasopharynx. This might also help explain the high interindividual variation in bacterial community structure observed in our swab cohort, a pattern similarly reported in other body sites directly exposed to the environment, such as the oral cavity (35).

Consistent with previous studies in Western Australian children (6,12), the nasal bacterial profiles in our cohort comprised both commensal and opportunistic taxa, particularly various species from the genera *Moraxella* and *Streptococcus*. Notably, *Streptococcus pneumoniae* was significantly enriched in symptomatic swabs, although its overall prevalence in the cohort was low (~11%) but comparable to the detection rates reported in previous research using nasal swabs (9). In contrast, the abundance of *Moraxella catharralis*, which has previously been shown to increase during viral respiratory infections (9,12,36),

did not differ between background and symptomatic swabs. The prevalence of *Moraxella* species was high in our cohort, both in background and symptomatic swabs, which contrasts with previous research conducted in Perth where early-life nasopharyngeal colonization by *Moraxella* was not observed (12). This difference might, in part, reflect the introduction of pneumococcal conjugate vaccines into Australia's National Immunization Program for all children since 2005, although associations between pneumococcal vaccination and upper airway colonization by *Moraxella* remain inconsistent across studies (37,38).

Despite the high viral burden observed in symptomatic swabs, most of which tested positive for either rhinovirus or SARS-CoV-2, community-level analyses revealed no significant differences in overall microbial composition, alpha diversity, or bacterial load between background and symptomatic swabs. This contrasts with several previous studies that reported reduced microbial diversity and increased dominance of pathogenic taxa from the genera *Streptococcus*, *Moraxella*, or *Haemophilus* during viral respiratory infections (6,36,39). We suggest this discrepancy might be due to the high interindividual variability in microbial composition within our cohort and the limited sample size. Notably, when comparing longitudinal samples from the same participants, we observed a significant reduction in bacterial alpha diversity in symptomatic swabs. Additionally, different viruses might also interact with nasal bacterial communities in distinct ways. Consistent with this, multilevel virus–bacteria interactions were observed in rhinovirus-positive swabs but not in those positive for SARS-CoV-2. Rhinovirus-positive symptomatic swabs exhibited lower bacterial alpha diversity compared to those infected with SARS-CoV-2; however, this difference was not observed in co-infected samples. Additionally, rhinovirus detection was positively correlated with the abundance of *Moraxella catarrhalis* and negatively with *Streptococcus*. Differential abundance analysis further revealed a significant enrichment in *Moraxella catarrhalis* in rhinovirus-positive swabs. The interaction between *Moraxella catarrhalis* and rhinovirus has been previously reported, with evidence suggesting that rhinovirus might enhance the pathogenicity of *Moraxella catarrhalis* and increase its abundance following infection (9,33,40). Interestingly, we did not observe significant correlations between bacterial taxa and SARS-CoV-2 detection, possibly reflecting differences in evolutionary history. While rhinoviruses might have co-

evolved with humans, fostering stable interactions with the respiratory microbiota, the recent emergence of SARS-CoV-2 might not yet support such ecological associations.

Using probabilistic modelling of the bacterial community structure, we identified two endotypes: a low-diversity, *Moraxella*-dominated endotype (endotype 1) and a *Streptococcus*-dominated endotype (endotype 2). These endotypes were not associated with demographic or environmental factors such as sex, seasonality, or childcare attendance. However, they were differentially associated with respiratory outcomes in a sex-specific manner. Endotype 1, when detected in background swabs, was linked to an increased rate of wheezing episodes, particularly among females. Additionally, detection of endotype 1 in background swabs showed a trend toward earlier wheezing onset. Although sex-specific predictors of wheeze have been described (34), a sex-specific association with the nasal microbiota has not been reported. Our results linking endotype 1 with wheeze are consistent with previous studies showing that early colonization with *Moraxella catarrhalis* increases the risk for recurrent wheeze and asthma in early life (11, 41). Notably, in addition to the abundance of *Moraxella catarrhalis*, endotype 1 was also characterized by the abundance of *Moraxella nonliquefaciens*. While *Moraxella catarrhalis* has been strongly implicated in asthma pathogenesis, the roles of other *Moraxella* species remain less well-defined, with some studies reporting conflicting associations regarding the presence of *Moraxella* in the nasopharynx and respiratory health (13-15). For example, a recent study identified *Moraxella lincolnii* in association with asthma (39). Thus, although both *Moraxella lincolnii* and *Moraxella nonliquefaciens* are generally considered commensals of the respiratory tract, their presence in the airways during early life might still be relevant in the etiology of wheezing phenotypes.

Temporal analysis of endotype stability in longitudinal samples revealed that most individuals retained their initial endotype during symptomatic episodes, particularly those with background swab communities classified as endotype 1. Interestingly, we observed transitions from endotype 2 to endotype 1 during a symptomatic episode, but not the reverse, suggesting that endotype 1 is relatively stable over the time. Similar findings have been reported in the nasopharynx, where *Moraxella*-dominated communities showed the highest

stability between two consecutive healthy samples (6). A comparable pattern
has also been observed in patients with chronic obstructive pulmonary disease
(COPD), where the acquisition of a *Haemophilus*-dominated airway microbiota
appears to limit microbial community reconfiguration over the time (42). While
different transition groups in our cohort were not associated with respiratory
phenotypes in the first year of life, they could reflect distinct inflammatory
profiles in response to symptomatic episodes, as it has been observed in COPD
(42).
Our pilot study differs from previous research in the field in several key aspects.
We amplified and sequenced the full length *16S rRNA* locus, which provides
more accurate species-level taxonomic resolution, unlike studies that focus on
shorter fragments of the *16S rRNA* gene (16). We minimized the impact of
contaminating sequences in the bacterial profiles of our cohort by quantifying
bacterial load and retaining only samples with significant bacterial DNA
presence compared to extraction controls. Additionally, we utilized a purpose-
designed smartphone app for real-time monitoring of respiratory symptoms,
thereby minimizing bias associated with parent-reported data and recall
limitations (17,20). We also acknowledge several limitations in our study. First,
AERIAL is a single-center study (17), which might limit the generalizability of our
findings to broader populations. Second, sample collection occurred between
November 2021 and January 2023, a period following the COVID-19 lockdowns
in Western Australia. To enable timely sampling despite public health
restrictions, parents were trained to collect nasal swabs at home. However,
these public health measures might have influenced the circulation and
prevalence of respiratory viruses in the cohort (43). Third, our pilot study
involved a relatively small sample size and was limited to two consecutive
timepoints in the longitudinal analysis. Given the high individual variability, the
small sample might have reduced statistical power to detect complex
interactions and increased sensitivity to outliers. For instance, the observed
sex-endotype interaction was influenced by a single participant with an
unusually high number of wheezing episodes. While biologically plausible, such
findings require confirmation in larger cohorts. Lastly, as with all amplicon-
based studies, our microbial profiling approach does not provide functional

insights into how the nasal microbiota might modulate responses to viral
infections.
571
Conclusion
In conclusion, this pilot observational study provides new evidence that early-life
nasal bacterial communities, particularly when stratified into compositional
endotypes, might be linked to wheezing risk in a sex-specific manner. Although
preliminary, these findings highlight the potential utility of microbial profiling for
early risk stratification of respiratory disease susceptibility and warrant
validation in larger, independent cohorts.
579

580 **Ethics approval.**
581 The AERIAL study was approved by Ramsey Health Care HREC WA-SA,
582 reference number 1908. Informed consent was obtained from the parents or
583 caregivers of all children participating in the AERIAL study.
584

Data availability.
The taxonomy table and all de-identified datasets used for analysis are
available as supplemental material and in the accompanying GitHub repository:
https://github.com/jacapmar/MicrobiomeAERIAL. Due to ethical considerations
regarding participant confidentiality, raw sequencing files cannot be made
publicly available, however the supplemental de-identified datasets are
sufficient for reproducing all reported findings. The R code is also available in
the GitHub repository.
593

594 **Conflict of interests.**
595 AB is a co-founder, equity holder, and director of the startup company
596 Respiradigm Pty Ltd that is related to this work. AB is the founder of the startup
597 company INSiGENe Pty Ltd that is unrelated to this work. No other authors
598 have conflict of interest to disclose.
599

600 **Acknowledgments.**
601 We are grateful to all participants in the AERIAL study and their families. Their
602 willingness to adapt to COVID pandemic protocols and self-collect nasal swab

samples enabled our study to continue. We acknowledge the AERIAL clinical staff: Bailee Renouf, Amy Greenly, Angela Fuery, Jodie Leslie, Tanya Betty, Suzie Cooper, AERIAL laboratory staff: Ashleigh Heng-Chin, Luke Berry, Courtney Kidd, Minda Amin, and ORIGINS staff at Western Diagnostics Pathology: Fiona Rynne and Allan Albornoz for their continuous support and contribution towards the AERIAL study.

AERIAL is a sub-project of ORIGINS. This unique long-term study, a collaboration between The Kids Research Institute Australia and Joondalup Health Campus, is one of the most comprehensive studies of pregnant women and their families in Australia to date, recruiting 10,000 families over a decade from the Joondalup and Wanneroo communities of Western Australia. We are grateful to all the ORIGINS families who support the project. We would also like to acknowledge and thank the following teams and individuals who have made ORIGINS possible: ORIGINS team; Joondalup Health Campus (JHC); members of the ORIGINS Community Reference and Participant Reference Groups; Research Interest Groups and the ORIGINS Scientific Committee; The Kids Research Institute Australia; City of Wanneroo; City of Joondalup; and Professor Fiona Stanley. ORIGINS has received core funding support from the Telethon Perth Children's Hospital Research Fund, Joondalup Health Campus, the Paul Ramsay Foundation, and the Commonwealth Government of Australia through the Channel 7 Telethon Trust. Substantial in-kind support has been provided by The Kids Research Institute Australia and Joondalup Health Campus.

S.M.S. received funding from the National Health and Medical Research Council (project grant number NHMRC115648) to support the AERIAL study and is also recipient of a NHMRC Investigator grant (NHMRC 2007725). A.K. is a Rothwell Family Fellow. T.I. is supported by a Stan Perron Charitable Foundation People Fellowship. S.P.A.-R. received funding from the Branchi family. A.B. is supported by the NIH (R21 AI176305-01A1, R01AI099108-11A1).

Author Contributions: J.A.C.-M., E.K.-S., P.A.-R., D.G.H., T.I., Y.V.K., D.J.M., G.Z., L.T., D.T.S., A.B., S.L.P., P.N.L., A.K. and S.M.S participated in the conceptualization of the study. J.A.C.-M. optimized the extraction protocol and

performed the extraction and quantification of the microbial DNA. J.A.C.-M. and
P.A.-R. carried out the computational analyses. J.A.C.-M. analyzed the data.
E.K.-S. coordinated the logistics of AERIAL study including collection of the
swab samples and associated metadata. E.K.-S. coordinated accession to the
stored samples and extracted the associated metadata. D.G.H. curated the
metadata associated with this specific study. S.M.S. conceived the AERIAL
study and obtained the funding to support this study. J.A.C.-M. prepared the
figures and the original draft for publication. All the authors participated in
critical discussions about the results presented in this manuscript as well as in
the revision and proof reading of the manuscript.

Figure Legends.

Figure 1. A. The bar plot shows the overall relative abundance (%) of the top
10 ASVs in our dataset. **B**. Heatmap summarizing the Spearman correlation
analysis between the centered log-ratio transformed counts of the top three
ASVs and the two most frequently detected viruses. Heatmap colors indicate
the direction of the correlation—positive (red) or negative (blue)—with color
intensity reflecting the Spearman's ρ (rho) coefficient. Both the correlation
coefficient and the FDR-adjusted *p*-value are shown within each cell. P-values
were corrected for multiple comparisons using the false discovery rate (FDR)
method. **C-D**. Boxplots representing alpha diversity (**C**, Shannon index) or
bacterial load (**D**) in symptomatic swabs based on the detected virus. RHV:
rhinovirus. Boxplots are overlaid with density plots (blue), and individual
samples are shown as red dots. P-values for the indicated comparisons were
calculated using the Wilcoxon rank-sum test.

Figure 2. Boxplots representing the bacterial load (**A**, **C**) and alpha diversity
ecological parameters (**B**, **D**) associated with DNA extracts from nasal swabs in
this study. In panels **C** and **D**, boxplots represent paired nasal swab specimens,
with samples obtained from the same infant at scheduled visits (background)
and during the subsequent symptomatic episode connected by straight lines.

Figure 3. A. Principal component analysis illustrating the linear projection of the
compositional profiles of the microbiota onto the first and third component of the

model, with each sample labelled according to its DMM-model based endotype membership. **B.** Heatmap summarizing the microbial profiles grouped by Dirichlet component. Rows represent the indicated ASVs ordered by their contribution to each component from top to bottom. For simplicity only the 10 top ASVs are represented. The color intensity in the heatmap corresponds to the square root of each ASV's relative abundance. Narrow columns represent individual swab samples, while wide columns show the mean abundance of each ASV within the Dirichlet components. **C.** Boxplots representing alpha diversity (Shannon index) in relation to the two microbial community types or endotypes represented in (**A**). **D.** Predicted age at first wheeze (in months) with 95% confidence intervals, stratified by nasal microbial endotypes. The slope estimate, adjusted R², and *F*-test results of the fitted linear model are shown at the top of the figure. **E.** Number of wheezing episodes in relation to the predicted values from the negative binomial model. The grey points represent individual observed data points, while the bars display the mean observed values for each endotype by sex, with error bars indicating the standard error of the mean. The red diamonds represent the predicted number of wheezing episodes from the negative binomial model. Sample size for each group (N) is shown at the base of each bar. Means were compared using z-tests with FDR adjustment for multiple comparisons. A sensitivity analysis associated with this panel is shown in supplemental Figure S11.

Table 1. Patient demographics and swab characteristics. HMPV, human metapneumovirus; RSV, respiratory syncytial virus. *, four SARS-CoV-2–positive swabs also tested positive for other viruses. Similarly, four rhinovirus-positive swabs and one parainfluenza-positive swab were co-infected with additional viruses. All adenovirus-positive swabs were detected in combination with other viruses.

Characteristics	Total number of infants n=55
Sex, n (%)	
Male	25 (46%)
Female	30 (54%)
Nasal swabs type, n (%)	

Scheduled visits (background)	41 (45%)
Symptomatic swabs	49 (55%)
Background swabs age (months), n (%)	
3 months of age	24 (58.5%)
6 months of age	15 (36.6%)
9 months of age	2 (9.4%)
Viral detection by swab type, n (%)	
Scheduled visits (background)	2 (4.8%)
Symptomatic swabs	48 (98%)
Number of swabs by virus detected, n (%)	
Rhinovirus *	28 (56%)
SARS-CoV-2 *	23 (46%)
Adenovirus *	2 (4%)
Parainfluenza *	2 (4%)
HMPV	1 (2%)
RSV	1 (2%)

References:

1.   United Nations Inter-agency Group for Child Mortality Estimation (UN
IGME), 'Levels & Trends in Child Mortality: Report 2019, Estimates developed
by the United Nations Inter-agency Group for Child Mortality Estimation'
[Internet]. United Nations Children's Fund. 2019 [cited August 2024]. Available
from: https://www.unicef.org/media/60561/file/UN-IGME-child-mortality-report-
2019.pdf.
2.   van Meel ER, Mensink-Bout SM, den Dekker HT, Ahluwalia TS, Annesi-
Maesano I, Arshad SH, et al. Early-life respiratory tract infections and the risk of
school-age lower lung function and asthma: a meta-analysis of 150 000
European children. Eur Respir J. 2022;60(4).
3.   Kusel MM, Kebadze T, Johnston SL, Holt PG, Sly PD. Febrile respiratory
illnesses in infancy and atopy are risk factors for persistent asthma and wheeze.
Eur Respir J. 2012;39(4):876-82.
4.   Global Initiative for Asthma. Global Strategy for Asthma Management
and Prevention, 2023. Updated July 2023. Available from: www.ginasthma.org
5.   de Steenhuijsen Piters WAA, Watson RL, de Koff EM, Hasrat R, Arp K,
Chu M, et al. Early-life viral infections are associated with disadvantageous
immune and microbiota profiles and recurrent respiratory infections. Nat
Microbiol. 2022;7(2):224-37.
6.   Teo SM, Tang HHF, Mok D, Judd LM, Watts SC, Pham K, et al. Airway
Microbiota Dynamics Uncover a Critical Window for Interplay of Pathogenic
Bacteria and Allergy in Childhood Respiratory Disease. Cell Host Microbe.
2018;24(3):341-52 e5.

7.   Wang L, Quinn B, Duliman J, Denn E. Maternal nasal microbiota seed
the offspring nasal microbiota in early infancy. Journal of Allergy and Clinical
Immunology. 2024;153(2).
8.   McCauley KE, DeMuri G, Lynch K, Fadrosh DW, Santee C, Nagalingam
NN, et al. Moraxella-dominated pediatric nasopharyngeal microbiota associate
with   upper   respiratory   infection   and   sinusitis.   PLoS   One.
2021;16(12):e0261179.
9.   Kloepfer KM, Lee WM, Pappas TE, Kang TJ, Vrtis RF, Evans MD, et al.
Detection of pathogenic bacteria during rhinovirus infection is associated with
increased respiratory symptoms and asthma exacerbations. J Allergy Clin
Immunol. 2014;133(5):1301-7, 7 e1-3.
10.   Luna PN, Hasegawa K, Ajami NJ, Espinola JA, Henke DM, Petrosino JF,
et al. The association between anterior nares and nasopharyngeal microbiota in
infants hospitalized for bronchiolitis. Microbiome. 2018;6(1):2.
11.   Bisgaard H, Hermansen MN, Buchvald F, Loland L, Halkjaer LB,
Bonnelykke K, et al. Childhood asthma after bacterial colonization of the airway
in neonates. N Engl J Med. 2007;357(15):1487-95.
12.   Teo SM, Mok D, Pham K, Kusel M, Serralha M, Troy N, et al. The infant
nasopharyngeal microbiome impacts severity of lower respiratory infection and
risk of asthma development. Cell Host Microbe. 2015;17(5):704-15.
13.   Biesbroek G, Tsivtsivadze E, Sanders EA, Montijn R, Veenhoven RH,
Keijser BJ, et al. Early respiratory microbiota composition determines bacterial
succession patterns and respiratory health in children. Am J Respir Crit Care
Med. 2014;190(11):1283-92.
14.   Yu X, Wang L, Zheng, X, Wen Y, Zhang Z, Fan L, et al. Moraxella
occupied the largest proportion in the nasal microbiome in healthy children,
which   potential   protect   them   from   COVID-19.   Microb   Pathog.   2022;
170:105685.
15.   van den Munckhof EHA, Hafkamp HC, de Kluijver J, Kuijper EJ, de
Koning MNC, Quint WGV et al. Nasal microbiota dominated by Moraxella spp.
Is associated with respiratory health in the elderly population: a case control
study. Respir Res. 2020; 21(1):181.
16.   Johnson JS, Spakowicz DJ, Hong BY, Petersen LM, Demkowicz P, Chen
L, et al. Evaluation of 16S rRNA gene sequencing for species and strain-level
microbiome analysis. Nat Commun. 2019;10(1):5029.
17.   Kicic-Starcevich E, Hancock DG, Iosifidis T, Agudelo-Romero P,
Caparros-Martin JA, Karpievitch YV, et al. Airway epithelium respiratory
illnesses and allergy (AERIAL) birth cohort: study protocol. Front Allergy.
2024;5:1349741.
18.   Silva DT, Hagemann E, Davis JA, Gibson LY, Srinivasjois R, Palmer DJ,
et al. Introducing the ORIGINS project: a community-based interventional birth
cohort. Reviews on Environmental Health. 2020;35(3):281-93.
19.   D'Vaz N, Kidd C, Miller S, Amin M, David JA, Talati Z, et al. The
ORIGINS project biobank: a collaborative bio resource for investigating the
developmental origins of health and disease. Int J Environ Res Public Health.
2023; 20(13):6297.
20.   Hancock DG, Kicic-Starcevich E, Sondag T, Rivers R, McGee K,
Karpievitch YV, et al. Real time monitoring of respiratory viral infections in
cohort studies using a smartphone app. iScience. 2024; 27(10):110912.

21. Caparros-Martin JA, Lareu RR, Ramsay JP, Peplies J, Reen FJ,
Headlam HA, et al. Statin therapy causes gut dysbiosis in mice through a PXR-
dependent mechanism. Microbiome. 2017;5(1):95.
22. Eisenhofer R, Minich JJ, Marotz C, Cooper A, Knight R, Weyrich LS.
Contamination in Low Microbial Biomass Microbiome Studies: Issues and
Recommendations. Trends Microbiol. 2019;27(2):105-17.
23. Saladie M, Caparros-Martin JA, Agudelo-Romero P, Wark PAB, Stick
SM, O'Gara F. Microbiomic analysis on low abundant respiratory biomass
samples; improved recovery of microbial DNA from bronchoalveolar lavage
fluid. Front Microbiol. 2020;11:572504.
24. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes
SP. DADA2: High-resolution sample inference from Illumina amplicon data. Nat
Methods. 2016;13(7):581-3.
25. Di Tommaso P, Chatzou M, Floden EW, Barja PP, Palumbo E,
Notredame C. Nextflow enables reproducible computational workflows. Nat
Biotechnol. 2017;35(4):316-9.
26. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for
rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl
Environ Microbiol. 2007;73(16):5261-7.
27. Parks DH, Chuvochina M, Waite DW, Rinke C, Skarshewski A, Chaumeil
PA, et al. A standardized bacterial taxonomy based on genome phylogeny
substantially revises the tree of life. Nat Biotechnol. 2018;36(10):996-1004.
28. Caparros-Martin JA, Saladie M, Agudelo-Romero SP, Reen FJ, Ware
SW, Sly PD, et al. Detection of bile acids in bronchoalveolar lavage fluid defines
the inflammatory and microbial landscape of the lower airways in infants with
cystic fibrosis. Microbiome. 2023;11:132.
29. Davis NM, Proctor DM, Holmes SP, Relman DA, Callahan BJ. Simple
statistical identification and removal of contaminant sequences in marker-gene
and metagenomics data. Microbiome. 2018;6(1):226.
30. Rohart F, Gautier B, Singh A, Le Cao KA. mixOmics: An R package for
'omics feature selection and multiple data integration. PLoS Comput Biol.
2017;13(11):e1005752.
31. Holmes I, Harris K, Quince C. Dirichlet multinomial mixtures: generative
models for microbial metagenomics. PLoS One. 2012;7(2):e30126.
32. Lin H, Peddada SD. Multigroup analysis of compositions of microbiomes
with covariate adjustments and repeated measures. Nat Methods.
2024;21(1):83-91.
33. Bosch AA, Biesbroek G, Trzcinski K, Sanders EA, Bogaert D. Viral and
bacterial interactions in the upper respiratory tract. PLoS Pathog.
2013;9(1):e1003057.
34. Tse SM, Rifas-Shiman SL, Coul BA, Litonjua AA, Oken E, Gold DR. J
Allergy Clin Immunol 2016; 138(6):1561-1568.
35. Human Microbiome Project Consortium. Structure, function and diversity
of the healthy human microbiome. Nature. 2012. 486(7402):207-214.
36. Allen EK, Koeppel AF, Hendley JO, Turner SD, Winther B, Sale MM.
Characterization of the nasopharyngeal microbiota in health and during
rhinovirus challenge. Microbiome. 2014;2:22.
37. Revai K, McCormick DP, Patel J, Grady JJ, Saeed K, Chonmaitree T.
Effect of pneumococcal conjugate vaccine on nasopharyngeal bacterial
colonization during acute otitis media. Pediatrics. 2006; 117(5):1823-1829.

38. Biesbroek G, Wang X, Keijser BJF, Eijkemans RMJ, Trzcinski K, Rots
NY, et al. Seven-valent pneumococcal conjugate vaccine and nasopharyngeal
microbiota in healthy children. Emerg Infect Dis. 2014; 20(2):201-210.
39. Korten I, Mika M, Klenja S, Kieninger E, Mack I, Barbani MT, et al.
Interactions of Respiratory Viruses and the Nasal Microbiota during the First
Year of Life in Healthy Infants. mSphere. 2016;1(6).
40. Dissanayake E, Brockman-Schneider RA, Stubbendieck RM, Helling BA,
Zhang Z, Bochkov YA et al. Rhinovirus increases Moraxella catarrhalis
adhesion to the respiratory epithelium. Front Cell Infect Microbiol. 2023.
12:1060748.
41. Thorsen J, Li XJ, Peng S, Sunde RB, Shah SA, Bhattacharyya M et al.
The airway microbiota of neonates colonized with asthma-associated
pathogenic bacteria. Nat Commun. 14(1):6668.
42. Wang Z, Locantore N, Haldar K, Ramsheh MY, Beech AS, Ma W et al.
Inflammatory endotype-associated airway microbiome in chronic obstructive
pulmonary disease clinical stability and exacerbations: a multicohort longitudinal
analysis. Am J Respir Crit Care Med. 2021. 203(12):1488-1502.
43. Chow EJ, Uyeki TM, Chu HY. The effects of the COVID-19 pandemic on
community respiratory virus activity. Nat Rev Microbiol. 2023;21(3):195-210.